Summary Currently, the clinical use of 5-aminolaevulinic acid (ALA)-induced protoporphyrin IX (PPIX) for photodynamic therapy (PDT) is limited by the maximum tolerated oral ALA dose (60 mg kg-'). This study investigates whether hydroxypyridinone iron-chelating agents can be used to enhance the tissue levels of PPIX, without increasing the administered dose of ALA. Quantitative charge-coupled device (CCD) fluorescence microscopy was employed to study PPIX fluorescence pharmacokinetics in the colon of normal Wistar rats. The iron chelator, CP94, when administered with ALA was found to produce double the PPIX fluorescence in the colonic mucosa, compared with the same dose of ALA given alone and to be more effective than the other iron chelator studied. CP20. Microspectrofluorimetric studies demonstrated that PPIX was the predominant porphyrin species present. PDT studies conducted on the colonic mucosa showed that the simultaneous administration of 100 mg kg-' CP94 i.v. and 50 mg kg-' ALA i.v. produced an area of necrosis three times larger than similar parameters without the iron-chelating agent with the same light dose. It is possible, therefore, to increase the amount of necrosis produced by ALAinduced PDT substantialty, without increasing the administered dose of ALA, through the simultaneous administration of the iron-chelating agent, CP94.
Photodynamic therapy (PDT) is a non-thermal technique in which a preadministered photosensitizer is activated w-ith light of a specific wavelength. so that a cytotoxic species can be formed from molecular oxygen. thus. producing localized tissue necrosis (Bow-n. 1989 (MacRobert. 1994) . Preliminarv clinical studies. however. have only shown superficial necrosis with the maximum tolerated oral dose (60 mg kg-1). Methods to increase the effectiveness of this treatment modalitv. waithout increasing the administered ALA dose. are therefore beinc inv-estigated. 'ith the effects of ironchelating agents being studied in this paper.
The hydroxypy ridinones are a relativels newa series of ironchelatincg agents. They can be administered orally and enter the intracellular iron pools rapidlN. being both neutrally charged and of lowa molecular weig-ht (Hoy es and Porter. 1993) . Oririnallv developed to supersede desferrioxamine for the treatment of thalassaemia and other disorders of iron overload. the hydroxvpyridinones are now beincg investicated to enhance ALA-induced PDT. They do this by chelatincg iron. thus reducincg the conversion of PPIX to haem. resultincg in an even greater accumulation of PPIX and. thus. a greater photodynamic effect (Chanc et al. 1997 ).
Tw o hVdroxypyridinones are studied in this paper: the 1.2-dimethyl derixative (CP2O) and the l.2-diethxl derivative (CP94). Both of these compounds has-e been given to patients with iron overload v ithout sicnificant toxicity and produced rapid and effective iron mobilization (Brittenham. 1992) .
MATERIALS AND METHODS Chemicals
ALA powder (ALA.HC1. 99% purity. DUSA Pharmaceuticals. NY. USA) was dissolved in physiological strength. phosphatebuffered saline (PBS. pH 2.8) and administered intravenously ('aith a concentration of 50 mc, ml and a maximum xolume of 0.2 ml). The iron chelators. CP2O and CP94. w'ere synthesized and kindly donated in powder form by the Department of Pharmacy.
Kinas Collegye. London. UK (90% and 95% purity respectively).
These were also prepared in PBS and administered intravenously ('aith a concentration of 100 mg, ml-' and a maximum volume of 0.2 ml). Separate syrines -ere always used for the iron chelator (1998) Phase contrast microscopy with a slow-scan cooled chargecoupled device (CCD) camera (Wright Instruments, Enfield, London, UK) was used to image and quantify fluorescence on the frozen sections. The fluorescence was excited using an 8-mW helium-neon laser (632.8 nm) and detected between 665 and 710nm using bandpass and longpass filters as described previously (Bedwell et al, 1992 All animals were recovered after surgery and killed after 3 days, as mucosal damage is maximal at this time (Barr et al, 1987) . The treated area of colon was excised, cut longitudinally and flattened out so that the lesion produced by the treatment could be photographed with a scale. This image was then scanned into a computer using a flat-bed scanner and image process software was used to determine the size of the area of necrosis, in the plane perpendicular to that of the treatment fibre. Representative specimens were fixed in formalin so that conventional light microscopy could confirm the macroscopic findings. This end point enabled a direct comparison of the treatment groups so that the most effective regime (the one which produced the most necrosis) could be determined.
RESULTS
Tissue fluorescence quantification Figure IA) shows that the level of fluorescence is considerably higher in the mucosa than the underlying muscle and peaks at 75 min (the time chosen for photodynamic studies). Figure lB shows the level of fluorescence produced if the iron-chelating agents are administered without ALA. There is a slight increase in fluorescence (particularly at 75 min) resulting from the effect of the iron chelators on the normal endogenous haem biosynthetic pathway. It should be noted that the background autofluorescence of the endogenous porphyrins from the colon of untreated control animals has been subtracted from all fluorescence measurements.
The simultaneous administration of CP94 with ALA ( Figure   1C ) doubles the peak fluorescence produced in the colonic mucosa. The fluorescence in the muscle does not increase significantly and remains low, resulting in a large difference between the mucosal and muscle layers. By administering CP94 30 min before ALA ( Figure 1D ), the enhancement of mucosal fluorescence is slightly reduced but it appears that the profile might change, so there is potentially a larger therapeutic window in which PDT treatment could be conducted. Figure IE and F shows the same treatment regimes but with CP20 instead of CP94. Although both treatments produce greater mucosal fluorescence than ALA alone, they do not produce the same degree of enhancement as CP94.
Fluorescence spectroscopy
Fluorescence spectra were recorded using the microscope from frozen sections of tissue taken from animals given each treatment regime and representative spectra from mucosal areas are shown in Figure 2 . The spectra from blank control sections (no compounds injected) were subtracted. There are no significant differences between the ALA only ( Figure 2A ) and combinations of CP94 and ALA ( Figure 2B ) or CP20 and ALA ( Figure 2C ) spectra, or in fact any other spectra recorded during this study, which demonstrates that the iron-chelating agents do not induce significant production of other fluorescent species. Maxima were at 636±2 nm in each case and the spectral profiles recorded conform to the standard PPIX emission spectra described by Dietel et al (1997) and Sailer et al (1997) . A previous high-performance liquid chromatography (HPLC) analysis of colon samples after intravenous administration of ALA to Wistar rats (Loh et al, 1993) has shown that PPIX is the predominant porphyrin present (>95%) and we can, therefore, conclude that the fluorescence measured in our present study is produced predominantly by PPIX.
Photodynamic effects
The area of necrosis (mm2) produced by each treatment regime is plotted in Figure 3 . Only the effects of CP94 on ALA-induced PDT were investigated because it was found to be the more promising iron chelator in the fluorescence studies. The time of CP94 administration relative to ALA administration was varied and the success of the PDT treatment regime determined by the area of necrosis produced. The simultaneous administration of 50 mg kg-' ALA i.v. and 100 mg kg-' CP94 i.v. was found to be the most effective, producing three times the area of necrosis of ALA alone. CP94 only plus light controls, laser only controls and drug only controls were also conducted, none of which produced any necrosis. The error bars were determined by calculating the standard error of the mean.
Histological analysis of fixed sections showed necrosis in all the treated groups. This was full thickness in places. It is likely that this occurred (even though the level of PPIX is much lower in the colonic muscle than the colonic mucosa) because of the high incident fluence rate used in this model, as well as the thinness of the rat colon. A combination of these factors may have allowed a sufficient level of light to penetrate into the muscle to cause necrosis. Even though full thickness necrosis was observed in some sections and large lesions (relative to the size of the rat colon) were produced in some cases, no animal showed evidence of colonic perforation or stenosis at post mortem (even though occasional lesions were circumferential) and no other abdominal organs appeared affected by the treatment.
DISCUSSION
PDT using ALA is limited clinically by the ALA dose which can be tolerated orally. It is thought that the transient elevation of liver enzymes found after oral administration of ALA is related to the high levels of ALA reaching the liver after absorption from the upper gastrointestinal tract. This is most probably due to the ALA itself, although it is difficult to be sure it is not due to the PPIX produced from the ALA. If it is due to the ALA, one way to overcome this problem may be the administration of an iron-chelating agent in combination with the ALA, as reported here. This enhances the effect of the treatment, producing more necrosis, without increasing the administered dose of ALA. This method further manipulates the haem biosynthetic pathway, as not only is the normal regulation of the pathway being avoided, by the exogenous administration of ALA resulting in all subsequent enzymes being forced to operate at maximal rate, but the iron chelator also inhibits the final step of the pathway (and the secondary ratelimiting point) by removing Fe2+ from the system. This results in an even greater accumulation of PPIX, which can then be utilized for PDT. In addition to this, the resultant low intracellular iron concentration also inhibits translation of ALA synthase mRNA, which would normally (without exogenous ALA administration) be a major point of regulation for this pathway (Cox et al, 1991) .
The hydroxypyridinones are a relatively new series of iron chelators which are well suited to this application by having lower molecular weights and greater lipophilicity than desferrioxamine, a clinically established iron chelator (Brittenham, 1992 Cooper et al. 1996) . It has greater affinity for iron than desferroxamine beina bidentate (rather than hexadentate). bindinc to iron in the ratio of 3:1 compared with 1: 1 with desferrioxamine (Hershko et al. 1991) .
Beino a relatively new series of compounds. relatively little research has been conducted investioatin2 the effects of the hydroxypyridinones on ALA-induced PDT. We have. however. previously found that CP94 enhanced porphyrin fluorescence and photosensitivity in all cell lines studied (Bech et al. 1997) . as well as doubling, the PPIX fluorescence in the urothelium of the normal rat bladder (when aiven in combination with ALA instilled in the bladder) (Chang et al. 1997 (Kennedy et al. 1996) .
We found it possible to convert the increased fluorescence observed in the pharmacokinetic study into increased necrosis with PDT. with a substantial threefold amplification being observed with the simultaneous administration of CP94 and ALA when compared with ALA alone. Although several different times of CP94 administration were investigated. this was found to be the most effective treatment regime and may be of value clinically.
Further study is. however. necessarv. and should include oral or topical application of CP94 in combination with ALA and the effects of these compounds in a tumour model in which the iron metabolism may be altered. We have. nonetheless. established that the iron-chelating agent. CP94. can be used to significantly increase the area of necrosis produced by ALA-induced PDT. in this model. without requiring an increase in the administered dose of ALA. Both iron-chelating agents have been administered intravenouslv in this study which is a convenient, accurate method of administration in this species. As all the compounds used in this study are normally administered orally to patients. further study with this mode of administration should be conducted.
